AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tourmaline Bio, Inc. Director's Dealing 2021

May 7, 2021

32658_dirs_2021-05-06_2c69d4d5-ba4f-47bd-9483-48eb45c1f707.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Talaris Therapeutics, Inc. (TALS)
CIK: 0001827506
Period of Report: 2021-05-06

Reporting Person: Fenton Mary Kay (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$6.79	2031-02-21	Common Stock (364485)		Direct

Footnotes

F1: The shares underlying this option shall vest as follows: 25% shall vest on January 25, 2022; and the remaining shall vest in 36 equal monthly installments thereafter.